About: Bhavneesh Sharma

Bhavneesh Sharma

Top 20 Ranking (28.2% Avg Return) --TipRanks

Bhavneesh Sharma is a contributing analyst at FATRADER where he covers biotechnology and pharmaceuticals. A market expert with a medical degree and MBA, he is ranked among the top 15 financial bloggers and top 100 overall financial experts (including Wall Street analysts) on TipRanks.

Bhavneesh holds a Master of Business Administration degree with specialization in finance and financial markets from New York University's Stern School of Business, ranked among top 3 finance MBAs in the country. He has authored several highly-cited peer reviewed scientific publications and was awarded the Young Investigator Award at the international level twice by the American Chest Foundation and American College of Chest Physicians.

Bhavneesh's main strategy is event-driven, covering companies with near-term catalysts like data releases, PDUFA, etc. He capitalizes on his years of clinical and research experience with financial expertise (DCF modeling, etc.) to find profitable event-driven investments in the volatile U.S. biotech/pharma sector.

Successful picks have included Juno Therapeutics (picked after clinical hold), Alnylam Pharmaceuticals (picked after clinical hold), Dynavax (doubled after CRL), Neurocrine Biosciences, Sage Therapeutics, Sarepta Therapeutics (picked after negative Adcom), Zogenix, Editas medicine, Teva Pharmaceuticals (picked after the drop below $15), Tobira Therapeutics (picked after trial failure, etc.). Tobira and Juno went on to be acquired.

He is also a registered financial adviser and widely followed contributor to Seeking Alpha and SumZero.

Story Archive

Where Is The Biotech Sector Headed Next After The Recent Plunge?

With the recent sharp plunge in the biotechnology sector, which exceeded the pullback in the broad U.S. equity markets, I am getting investor questions about my outlook for the biotech sector over the next few months and long-term. In this article, I will provide my near-term and long-term outlook for the biotech sector as well as mention some top acquisition candidates over the next 12 months.
By Bhavneesh Sharma

An Analysis of Karuna Therapeutics' Upcoming Phase 2 Schizophrenia Data Readout

Karuna Therapeutics (KRTX), which is trading below its recent IPO price, has a key price-moving data release later this year: Phase 2 data from a randomized, placebo-controlled trial of KarXT in treating patients with schizophrenia and acute exacerbation of psychosis.
By Bhavneesh Sharma

Eyeing Intercept Pharmaceuticals On New Drug Application to Treat Fibrosis Due to NASH

Intercept Pharmaceuticals (NASDA: ICPT) submitted a New Drug Application (NDA) last week for its obeticholic acid (OCA) treatment for patients with fibrosis due to nonalcoholic steatohepatitis (NASH). The company has requested a Priority Review from FDA which would reduce the anticipated review period to six months.
By Bhavneesh Sharma

Aimmune's Palforzia: The First Potential FDA Approved Oral Immunotherapy For Peanut Allergy

The FDA's Adcom panel voted on Friday to approve the use of Aimmune Therapeutics (AIMT)'s peanut desensitization therapy in children and teens with peanut allergy.
By Bhavneesh Sharma

Three Small Cap, Developmental Stage Biotechs Using AI/ Machine Learning In Drug Discovery

The use of Artificial Intelligence (AI) and Machine Learning (ML) in the field of drug discovery has exploded in recent years. Here are some examples of developmental stage small-cap biotech companies using it in drug target discovery.
By Bhavneesh Sharma

Investment Rationale For MeiraGTx, Gene Therapy Company and Acquisition Candidate

Shares in gene therapy company MeiraGTx (MGTX) are up 2x this year and have pulled back 30% from 52-week highs. I expect the upside momentum to resume considering upcoming data releases.
By Bhavneesh Sharma

Shorting Solid Biosciences Stock (SLDB)

Solid Biosciences (SLDB) stock was up 43% on Friday after an upgrade to Buy by Chardan Capital’s analyst Gbola Amusa. Meanwhile, insiders have been selling the stock all year, including the management.
By Bhavneesh Sharma

Notes On Esperion Therapeutics: Buy/Sell Or Hold?

Esperion Therapeutics has a key compound called Bempedoic acid (BPA) that lowers LDL cholesterol (LDL-C) by a different mechanism than statins. Once the Adcom window has passed later this year, short-term traders could attempt to play a run-up in the stock before PDUFA.
By Bhavneesh Sharma

Chiasma Stock Could See More Downside

Chiasma (CHMA) recently reported successful phase 3 data for its oral octreotide formulation, Mycapssa, in treating acromegaly (a syndrome due to excessive growth hormone). The stock had a brief pop and has pulled back after the announcement of a $55M secondary equity offering. I looked at the company and feel that the stock has more room to fall in the coming months.
By Bhavneesh Sharma

Sign Up Now - Free 15-Day Trial! Go! Fatty!